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Summary: Research diagnostic instruments such as the Structured Interview for Prodromal Syndromes (SIPS) are now 
able to reliably identify individuals with different types of psychosis risk syndromes (PRS). About one-third of individuals 
with PRS convert to a diagnosable psychotic disorder within three years of the initial assessment. Currently available 
randomized controlled trials of interventions aimed at reducing the rate of psychotic conversion of PRS are promising, but 
they are too small and too short in duration to provide definitive conclusions about effectiveness. Given the high level of 
false positives (i.e., most individuals with PRS do not progress to frank psychosis) and the lack of definitive evidence about 
effectiveness, we recommend a staged approach to intervention in PRS that only uses antipsychotic medication after 
other, more benign approaches have been tried. At present the best approach appears to be to develop high-quality case-
management systems for individuals with PRS that provide close follow-up, psychoeducation and psychosocial support 
to patients and family members, and, possibly, psychotherapeutic and pharmacological treatments (with antipsychotic 
medications or neuroprotective agents). The effectiveness of these proposed interventions needs to be tested in large 
randomized controlled trials that follow up subjects for at least three years.
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1.  What are psychosis risk syndromes (PRS)?  
The occurrence of schizophrenia, affective psychotic 
disorders and other psychotic conditions are traumatic 
for both affected individuals and their families. With a 
peak age of onset of 18 to 30 years, psychotic illnesses 
often interrupt development during the transition from 
adolescence to adulthood.[1] Following the examples 
set with chronic physical illnesses such as diabetes and 
heart disease, the scientific focus on psychotic illnesses 
has increasingly shifted to early intervention. The goals 
of this new approach are to reduce illness progression 
and morbidity and, in time, to develop viable preventive 
interventions.[2] As part of this scientific reorientation, 
there is a growing body of work focused on populations 
at ‘clinical high risk’ for psychoses and on adolescents 
and young adults in the putative prodromal phase of a 
first psychotic episode – at which time there is illness-
related deterioration in the functioning of the brain and 
in neurocognitive, social and role functioning.[3,4] 
In the past decade, research diagnostic instruments 
such as the Comprehensive Assessment of At Risk 
Mental States (CAARMS)[5] and the Structured Interview 
for Prodromal Syndromes (SIPS) have been used to 
identify high-risk individuals and to distinguish different 
types of psychotic risk syndromes (PRS).[6,7] The SIPS 
classifies three types of psychotic risk syndromes: Brief 
Intermittent Psychotic Syndrome (BIPS); Attenuated 
Positive Symptom Syndrome (APSS); and Genetic Risk 
and Deterioration Syndrome (GRDS). The transition of 
PRS individuals to diagnosable psychosis has been of 
particular interest to researchers;[8] the largest meta-
analysis available[9] reports an average transition rate of 
about 20% over the first year of follow-up and of about 
35% over the first three years of follow-up. Therefore, 
populations with PRS provide an important opportunity 
to develop a systematic scientific strategy for the earlier 
intervention and possible prevention of psychosis.
2.  Potential benefits and risks of intervening in PRS 
Interventions for PRS, which target subjects with 
minimally detectable symptoms falling below the 
threshold of a psychotic disorder, can be considered a 
form of secondary or targeted prevention. The major 
aims of clinical intervention in PRS are: a) to reduce 
prodromal symptoms and related problems such as 
social withdrawal and academic difficulties; b) to reduce 
the risk of the subsequent onset of frank psychosis; and 
c) to minimize treatment delay for the subgroup of PRS 
subjects that do develop a first episode of psychosis. 
However, the use of such preventive interventions has ·7· Shanghai Archives of Psychiatry, 2013, Vol.25, No.1
elicited ethical concerns. Identification as an individual 
with PRS can be associated with stigma and heightened 
anxiety, and the interventions themselves have potential 
short- and long-term side effects.[10] For instance, low-
dose antipsychotic treatments – the cornerstone of the 
first wave of interventions for PRS – have been associated 
with neurotoxic effects in some animal studies.[11-13] 
Moreover, most persons with PRS do not subsequently 
develop frank psychosis (false positives), so there are 
important cost-benefit considerations in recommending 
that all persons with PRS be referred for treatment. 
This raises the question of how to stage treatments 
to maximize prevention while minimizing harm. Some 
authors recommend phase-specific interventions 
that match the symptomatic presentation of PRS 
and that include more benign options before 
progressing to pharmacological treatments.[14,15] 
Psychosocial interventions should be a component of 
all interventions for individuals with PRS. They include 
crisis intervention, assistance in maintaining social 
functioning, psychoeducation for patients and their 
family members, and general social support. These 
basic psychosocial interventions can be augmented by 
other psychotherapeutic and psychopharmacological 
interventions depending on the specific needs of the 
patient. Cognitive-behavioral therapy has been shown to 
be superior to the simple monitoring of PRS patients over 
time,[16,17] but it may not be better than less structured 
supportive counseling.[18] Potential psychopharmacologic 
interventions for PRS have recently been broadened to 
include non-antipsychotic medications. In the critical 
phase during the first emergence of a psychotic disorder 
apoptopic processes might play a key role, so agents 
with preclinical or clinical evidence for neuroprotective 
properties that can reduce cell death[19,20] (including 
antidepressants[21,22] and omega-3-fatty acids[23]) have 
been considered as candidates for PRS interventions.
3 .     C u r r e n t   e v i d e n c e   o f   e f f e c t i v e n e s s   o f   i n t e r v e n t i o n s                                             
for PRS 
Several randomized control trials with follow-up 
times of 3 to 12 months have assessed the effectiveness 
of different types of interventions for PRS.[24-26] Cognitive 
behavioral therapy either on its own[17,18] or in combina-
tion with risperidone[25] and ethyl eicosapentaenoic acid 
(ethyl EPA)[23] have been shown to significantly reduce 
PRS transition rates. Cognitive behavioral therapy[16] and 
olanzapine[27] have been shown to significantly reduce 
the severity of the psychopathological symptoms of 
PRS. However, few studies followed up patients after 
the acute treatment phase, and those that do have 
long-term follow-up data[17,25,28] found that the reduced 
risk for transition in the active treatment group is not 
maintained over time. The one exception is the 2008 
study of ethyl EPA by Amminger and colleagues[23] which 
reported that 2.5 to 3.5 months of acute treatment 
produced a sustained reduced risk of transition for nine 
months after stopping the active treatment. 
There are also several ongoing randomized controlled 
trials with non-antipsychotic medications including ethyl 
EPA, D-serine, and sarcosine (see: www.clinicaltrials.
gov) and with family-based interventions.[29] It is too 
early to come to a definitive conclusion, but the weight 
of the evidence suggests that pharmacological and non-
pharmacological interventions can significantly reduce 
transition rates in PRS, perhaps by as much as two-thirds 
(i.e., from 30 to 10%).[30]
4.  The study of PRS in Shanghai
In collaboration with the Beth Israel Deaconess 
Medical Center at Harvard Medical School, we evaluated 
the reliability and validity of the Chinese version of the 
Structured Interview for Prodromal Symptoms (SIPS) 
and used it to assess the prevalence of PRS in individuals 
treated at the Psychological Counseling Center of the 
Shanghai Mental Health Center. The SIPS was translated 
in standard fashion from English to Chinese and back-
translated from Chinese to English. The resulting 
instrument had excellent inter-rater reliability when used 
by Chinese psychiatrists with 38 patients (ICC=0.96).[31] 
Over a 10-month period, we screened 2078 patients, 
directly interviewed 1444 patients, and identified 104 
(5.0%) who met PRS criteria. These 104 cases included 
68 (65.7%) subclassified with attenuated positive symptom 
syndrome (APSS) and 23 (22.4%) with genetic risk and 
deterioration syndrome (GRDS); the overall prevalence 
is similar to western samples though the proportion 
of GRDS is somewhat higher than elsewhere. Routine 
treatment by the outpatient clinicians (who were blind 
to the results of the SIPS assessment) included the 
prescription of antidepressants for 33 of these individuals 
and antipsychotic medications for 22 of them; the 53% 
(55/104) rate of pharmacological treatment for PRS is 
comparable to the rate reported in the North American 
Prodrome Longitudinal Study.[32] Naturalistic follow-up of 
these individuals six months after the initial assessment 
for PRS found that 49 (47.1%) never returned to the 
clinic, a possible reflection of the limited psychosocial 
intervention and support provided to persons with PRS 
in China. Among the 86 individuals followed up by the 
research group, 5 (5.8%) met SIPS criteria for a psychotic 
episode; this six-month transition rate is lower than the 
18% rate reported in western studies.[9] The reasons for 
the lower rate of transition are unclear, but it could be 
related to the higher proportion of the GRDS subtype of 
PRS and the relatively high age (maximum 45 years old) 
in our sample.
5.  Summary and conclusions 
Individuals with PRS can be reliably identified 
using clinical diagnostic tools such as the SIPS. Simply ·8· Shanghai Archives of Psychiatry, 2013, Vol.25, No.1
monitoring PRS subjects for the first signs of frank 
psychosis might be an effective means of reducing the 
delay between the onset of the first episode and the 
start of antipsychotic treatment for the subgroup of 
patients who might need it. The use of pharmacological 
and psychological interventions during the prodromal 
phase may decrease the severity of the PRS presenting 
symptoms and reduce the rate of transition to frank 
psychosis, but the clinical trials that have assessed these 
interventions have been under-powered and have not 
followed up patients long enough to provide a definitive 
answer about this crucial question. Further research is 
needed to determine whether initial treatment effects 
can be maintained. 
Chinese clinicians are now starting to pay attention 
to the early recognition and prevention of psychotic 
illnesses, particularly schizophrenia. As they identify and 
diagnose more individuals with PRS it is important that 
they expand their usual pharmacological approach to 
psychosis and include more benign interventions such 
as high-quality case management, psychoeducation, 
family treatment, and cognitive behavior therapy. Large 
randomized clinical trials that rigorously exam the long-
term effects of these interventions are needed both in 
China and elsewhere. This effort will require expanding 
the range of personnel who provide supportive care 
to individuals with PRS, training clinicians in the skills 
needed to provide community-based case management 
services, and mobilizing the administrative support and 
funding needed to conduct large, long-term studies. 
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